Drug Profile
Research programme: prostate cancer therapy - Ipsen/UroGene
Alternative Names: Prostate cancer therapy research programme: Beaufour Ipsen/UroGeneLatest Information Update: 01 Sep 2004
Price :
$50
*
At a glance
- Originator Ipsen; UroGene
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 01 Sep 2004 Discontinued - Preclinical for Prostate cancer in France (unspecified route)
- 01 Sep 2004 Discontinued - Preclinical for Prostate cancer in United Kingdom (unspecified route)
- 12 Jul 2004 This programme is still in active development - BIO 2004 Annual International Convention (BIO-2004)